N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark

International Journal of Epidemiology

Volumn 36, Issue 1, 2007, Pages 11-18

  Lower Jr , G M ^a   Nilsson, T ^b   Nelson, C E ^b   Wolf, H ^c   Gamsky, T E ^a   Bryan, G T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE;

CANCER; EPIDEMIOLOGY;

ACETYLATION; ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; DENMARK; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR EPIDEMIOLOGY; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SWEDEN; URBAN RURAL DIFFERENCE; URINALYSIS;

DENMARK; EURASIA; EUROPE; NORTHERN EUROPE; SCANDINAVIA; SWEDEN;

EID: 34447502330     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyl290     Document Type: Article

References (54)

1. Rehn L. Blasengeschwültse bei fuchsin-arbeitern. Arch Klin Chir 1895;50:588.
2. Hueper WC, Wiley FH, Wolfe HD et al. Experimental production of bladder tumors in dogs by administration of beta-naphthalene. J Ind Hyg Toxicol 1938;20:46.
3. Case RAM, Hosker ME. Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Part I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Brit J Ind Med 1954;11:75; Brit J Prev Soc Med 1945;8:39.
4. Hueper WC. Occupational and Environmental Cancer of the Urinary System. New Haven: Yale University Press, 1969, p. 465.
5. Cole P. Lower urinary tract. In: Schottenfield D (ed.). Cancer Epidemiology and Prevention: Current Concepts. Springfield, IL: Charles C Thomas, 1974, pp. 233-62.
6. Parkes HG. The epidemiology of the aromatic amine cancers. In: Searle CF (ed.). Chemical Carcinogens, Am Chem Soc Monograph, Vol. 173, Washington, D.C.: American Chemical Society, 1976, p. 462.
7. Stula EF, Barnes JR, Sherman H, Reinhardt CF, Zapp J. Urinary bladder tumors in dogs from 4,4′-methylene-bis(2-chloroaniline) (MOCA). J Environ Pathol Toxicol 1977;1:1.
8. Higginson J. Chronic toxicology - an epidemiologist's approach to the problem of carcinogenesis. Essays Toxicol 1976;77:29.
9. Cole P, Hoover R, Friedell GH. Occupation and cancer of the lower urinary tract. Cancer 1972;29:1250.
10. Anthony HM, Thomas GM. Tumors of the urinary bladder: An analysis of the occupations of 1,030 patients in Leeds, England. J Natl Cancer Inst 1970;45:879.
11. Cole P, Hoover R. Comments on: Tumors of the urinary bladder: An analysis of the occupations of 1,030 patients in Leeds, England by Anthony H and Thomas GJ. Natl Cancer Inst 1971;46:1111.
12. Cole P, Monson RR, Haning H, Friedell GH. Smoking and cancer of the lower urinary tract. New Engl J Med 1971;284:129.
13. Miller AB. The etiology of bladder cancer from the epidemiological viewpoint. Cancer Res 1977,37:2939.
14. Hoffman D, Masuda Y, Wynder EL. α-Naphthylamine and β-naphthylamine in cigarette smoke. Nature 1969;221:254.
15. Radomski J. Environmental bladder carcinogens. National Bladder Cancer Project. Investigators' Workshop. January 25-27 1976:20.
16. Miller JA, Miller FC. The metabolic activation of carcinogenic aromatic amines and amides. Prgr Exptl Tumor Res 1969;11: 273-301.
17. Weisburger JH, Weisburger EK. Biochemical formation and pharmacological, toxicological, and pathological properties of hydroxylamines and hydroxamic acids. Pharmacol Rev 1973;25:1.
18. Clayson DB, Garner RC. Carcinogenic aromatic amines and related compounds. In: Searle CE (ed.). Chemical Carcinogens, Am Chem Soc Monograph, Vol. 173, Washington, D.C.: American Chemical Society, 1976, p. 366.
19. Radomski JL, Brill E. Bladder cancer induction by aromatic amines; role of N-hydroxy metabolites. Science 1970;167:992.
20. Radomski JL, Brill E, Deichmann WB, Glass EM. Carcinogenicity testing of N-hydroxy and other oxidation and decomposition products of 1- and 2-naphthylamine. Cancer Res 1971;31:1461.
21. Miller EC, Miller JA, Enomoto M. The comparative carcinogenicities of 2-acetylaminofluorene and its N-hydroxy metabolite in mice, hamsters, and guinea pigs. Cancer Res 1964,23:2018.
22. Poirier LA, Miller JA, Miller EC. The N- and ring-hydroxylation of 2-acetylaminofluorene and the failure to detect N-acetylation of 2-aminofluorene in the dog. Cancer Res 1963;23:790.
23. Lower GM, Jr, Bryan GT, Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytorol of species displaying different organ susceptibilities. Biochem Pharmacol 1973;22:1581.
24. Lower GM, Jr, Bryan GT. Enzymatic deacetylation of carcinogenic arylacetamides by tissue microsomes of the dog and other species. J Toxicol Environ Health 1976;1:421.
25. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964;63:394.
26. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharm Therap 1977;22:251.
27. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis 1954;70:266.
28. Devadatta S, Gangadharam PRJ, Andrews RH, Fox W, Ramakrishnan CV, Selkon JB, Velu S. Peripheral neuritis due to isoniazid. Bull WHO 1960; 23:587.
29. Evans DAP, Davidson K, Pratt RTC. The influence of acetylator phenotype on the effects of treating depression with phenelzine. Clin Pharmacol Therap 1965;6:430.
30. Perry HM, Jr, Sakamoto A, Tan EM. Relationship of acetylating enzyme to hydralazine toxicity. J Lab Clin Med 1967;70:1020.
31. Das KM, Eastwood NA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New Engl J Med 1973;289:491.
32. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. Isoniazid and ipromiazid: Activation of metabolites to toxic intermediates in man and rat. Science 1976;193:901.
33. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289.
34. Mitchell JR, Thorgeirsson UP, Black M et al. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relations to hydrazine metabolites. Clin Pharmacol Therap 1975;18:70.
35. Woosley RL, Nies AS, Drayer D, Reidenberg M, Oates JA. Aceylator phenotype as a factor in procainamide-induced lupus erythematosus. Clin Res 1977;25:279A.
36. Reidenberg MM, Martin JH. The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Disposition 1974;2 71.
37. McLaren HH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathology. Brit Med J 1977;2:291.
38. Glowinski I, Radtke HE, Weber WW. Genetic susceptibility to chemical carcinogenesis from aromatic amines. Pharmacol 1976;18:231.
39. Anonymous. Cancer Incidence in Sweden 1971. National Board of Health and Welfare, the Cancer Registry, S-106 30 Stockholm, Sweden, 1975.
40. Clemmensen J. Statistical Studies in the Aetiology of Malignant Neoplasms. Vol V. Trends and Risks, Denmark 1943-1977. Acta Pathol Microbiol Scand 1977;(Suppl 261):286.
41. Weber WW, Brenner W. A filter paper method for determining isoniazid acetylator phenotype. Am J Human Genet 1974;26:467.
42. Armitage P. Statistical Methods in Medical Research. New York: Wiley, 1973, pp. 427-433.
43. Harris HW, Knight A, Selin MJ. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent - therapeutic and genetic implications. Am Rev Tuberc Pulm Dis 1958;78:944.
44. Hoover R, Mason TJ, McKay FW, Fraumeni JF, Jr. Cancer by county: New resources for etiologic clues. Science 1975;189:1005.
45. Lower GM, Jr, Bryan GT. Carcinogenesis and etiology: Natural systems approaches to causality and control. in: Javadopour N (ed.) Management of Urologic Cancers. Baltimore: Williams and Wilkins, 1978; Chap. 2.
46. King CM, Phillips B. Enzyme-catalyzed reactions of the carcinogen N-hydroxy-2-fluorenylacetamide with nucleic acid. Science 1968; 159:1351.
47. DeBaun JR, Miller EC, Miller JA. N-hydroxy-2-acetyl-aminofluorene sulfotransferase: Its probable role in carcinogenesis and in protein-(methion-5-yl) binding in rat liver. Cancer Res 1970;30 577.
48. Irving CC, Russell LT. Synthesis of the o-glucuronide of N 2-fluorenylhydroxylamine. Reaction with nucleic acids and with guanosine 5-monophosphate. Biochemistry 1970;9:2471.
49. Cardona RA, King CM. Activation of the o-glucuronide of the carcinogen N-hydroxy-FAA by enzymatic deacetylation in vitro Formation of FA-tRNA adducts. Biochem Pharmacol 1976;25 1051.
50. Kadlubar FF, Miller JA, Miller EC. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 1977;37:805.
51. Kellermann G, Shaw CR, Kellermann ML. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl J Med 1973; 289:934.
52. Kellermann G, Kellermann ML, Jett JR, Moses HL, Fontana RS. Aryl hydrocarbon hydroxylase in man and lung cancer. Human Genetics 1978;(Suppl. 1):161.
53. Higginson J. The role of the pathologist in environmental medicine and public health. Am J Pathol 1967;86:460.
54. Brody H. The systems view of man: Implications for medicine, science and ethics. Perspect Biol Med 1973;17:71.